© 2022 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Robert Busch; MD, Dhiren Patel, PharmD, CECES, BC-ADM; and Muthiah Vaduganathan, MD, MPH, review the role of SGLT-2 inhibitors in renal protection in patients with and without diabetes.
October 20th 2021
Dhiren Patel, PharmD, CECES, BC-ADM, Robert Busch, MD, and Muthiah Vadugananthan, MD, MPH, provide an overview of the prevalence of renal impairment in patients with diabetes.
An expert endocrinologist and cardiologist discuss the risks and complications of renal disease associated with diabetes and cardiovascular disease. Dr Robert Busch also provides an overview of some of the studies done in renal impairment.
Dr Robert Busch and Dr Muthiah Vadugananthan provide insights on educating their peers on the importance of decreasing renal progression.
Robert Busch, MD, and Muthiah Vadugananthan, MD, MPH, share their thoughts on the multifunctional responsibility of managing a patient’s renal disease.
A case study for a patient who required additional SGLT-2 inhibitors to help reduce progression of renal disease is presented, and Drs Robert Busch, Dhiren Patel, and Muthiah Vadugananthan share their final thoughts on renal protective agents.